Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

ZCMD vs IQV vs VEEV vs DOCS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ZCMD
Zhongchao Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • CN
Market Cap$7M
5Y Perf.-98.6%
IQV
IQVIA Holdings Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$30.32B
5Y Perf.-26.3%
VEEV
Veeva Systems Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$27.35B
5Y Perf.-45.9%
DOCS
Doximity, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$5.24B
5Y Perf.-55.3%

ZCMD vs IQV vs VEEV vs DOCS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ZCMD logoZCMD
IQV logoIQV
VEEV logoVEEV
DOCS logoDOCS
IndustryMedical - Healthcare Information ServicesMedical - Diagnostics & ResearchMedical - Healthcare Information ServicesMedical - Healthcare Information Services
Market Cap$7M$30.32B$27.35B$5.24B
Revenue (TTM)$27M$16.63B$3.20B$638M
Net Income (TTM)$-7M$1.39B$909M$239M
Gross Margin51.0%26.1%75.5%89.7%
Operating Margin-24.0%13.9%28.7%37.4%
Forward P/E14.1x19.0x16.8x
Total Debt$26K$16.17B$96M$12M
Cash & Equiv.$8M$1.98B$1.42B$210M

ZCMD vs IQV vs VEEV vs DOCSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ZCMD
IQV
VEEV
DOCS
StockJun 21May 26Return
Zhongchao Inc. (ZCMD)1001.4-98.6%
IQVIA Holdings Inc. (IQV)10073.7-26.3%
Veeva Systems Inc. (VEEV)10054.1-45.9%
Doximity, Inc. (DOCS)10044.7-55.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: ZCMD vs IQV vs VEEV vs DOCS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: DOCS leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. IQVIA Holdings Inc. is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. VEEV also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ZCMD
Zhongchao Inc.
The Defensive Pick

ZCMD is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.21, Low D/E 0.1%, current ratio 11.11x
Best for: sleep-well-at-night
IQV
IQVIA Holdings Inc.
The Value Play

IQV is the #2 pick in this set and the best alternative if value and momentum is your priority.

  • Lower P/E (14.1x vs 19.0x), PEG 0.35 vs 1.04
  • +16.5% vs ZCMD's -77.5%
Best for: value and momentum
VEEV
Veeva Systems Inc.
The Income Pick

VEEV is the clearest fit if your priority is income & stability and long-term compounding.

  • beta 0.77
  • 5.2% 10Y total return vs IQV's 166.5%
  • Beta 0.77, current ratio 4.89x
  • Beta 0.77 vs IQV's 1.33, lower leverage
Best for: income & stability and long-term compounding
DOCS
Doximity, Inc.
The Growth Play

DOCS carries the broadest edge in this set and is the clearest fit for growth exposure and valuation efficiency.

  • Rev growth 20.0%, EPS growth 54.2%, 3Y rev CAGR 18.4%
  • PEG 0.21 vs VEEV's 1.04
  • 20.0% revenue growth vs ZCMD's -28.3%
  • 37.5% margin vs ZCMD's -25.5%
Best for: growth exposure and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthDOCS logoDOCS20.0% revenue growth vs ZCMD's -28.3%
ValueIQV logoIQVLower P/E (14.1x vs 19.0x), PEG 0.35 vs 1.04
Quality / MarginsDOCS logoDOCS37.5% margin vs ZCMD's -25.5%
Stability / SafetyVEEV logoVEEVBeta 0.77 vs IQV's 1.33, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)IQV logoIQV+16.5% vs ZCMD's -77.5%
Efficiency (ROA)DOCS logoDOCS20.7% ROA vs ZCMD's -27.7%, ROIC 20.0% vs -30.1%

ZCMD vs IQV vs VEEV vs DOCS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ZCMDZhongchao Inc.
FY 2025
Service
93.9%$11M
Product
6.1%$696,442
IQVIQVIA Holdings Inc.
FY 2025
Research And Development Solutions
54.5%$8.9B
Technology And Analytics Solutions
40.6%$6.6B
Contract Sales And Medical Solutions
4.8%$788M
VEEVVeeva Systems Inc.
FY 2025
Subscription Services Veeva Research And Development
43.0%$1.2B
Subscription Services Veeva Commercial Cloud
40.2%$1.1B
Professional Services Veeva Research And Development
10.1%$277M
Professional Services Veeva Commercial Cloud
6.7%$185M
DOCSDoximity, Inc.
FY 2025
Subscription
95.3%$544M
Service, Other
4.7%$27M

ZCMD vs IQV vs VEEV vs DOCS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDOCSLAGGINGVEEV

Income & Cash Flow (Last 12 Months)

DOCS leads this category, winning 4 of 6 comparable metrics.

IQV is the larger business by revenue, generating $16.6B annually — 610.6x ZCMD's $27M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to ZCMD's -25.5%. On growth, VEEV holds the edge at +16.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricZCMD logoZCMDZhongchao Inc.IQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.
RevenueTrailing 12 months$27M$16.6B$3.2B$638M
EBITDAEarnings before interest/tax-$6M$3.5B$956M$250M
Net IncomeAfter-tax profit-$7M$1.4B$909M$239M
Free Cash FlowCash after capex-$4M$2.7B$1.4B$314M
Gross MarginGross profit ÷ Revenue+51.0%+26.1%+75.5%+89.7%
Operating MarginEBIT ÷ Revenue-24.0%+13.9%+28.7%+37.4%
Net MarginNet income ÷ Revenue-25.5%+8.3%+28.4%+37.5%
FCF MarginFCF ÷ Revenue-14.0%+16.1%+43.7%+49.2%
Rev. Growth (YoY)Latest quarter vs prior year-23.2%+8.4%+16.0%+9.8%
EPS Growth (YoY)Latest quarter vs prior year-20.3%+15.0%+23.9%-16.2%
DOCS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ZCMD leads this category, winning 4 of 7 comparable metrics.

At 22.8x trailing earnings, IQV trades at a 26% valuation discount to VEEV's 30.9x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.30x vs VEEV's 1.70x — a lower PEG means you pay less per unit of expected earnings growth.

MetricZCMD logoZCMDZhongchao Inc.IQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.
Market CapShares × price$7M$30.3B$27.4B$5.2B
Enterprise ValueMkt cap + debt − cash-$1M$44.5B$26.0B$5.0B
Trailing P/EPrice ÷ TTM EPS-1.15x22.79x30.92x23.45x
Forward P/EPrice ÷ next-FY EPS est.14.06x18.98x16.83x
PEG RatioP/E ÷ EPS growth rate0.56x1.70x0.30x
EV / EBITDAEnterprise value multiple12.97x28.40x21.14x
Price / SalesMarket cap ÷ Revenue0.60x1.86x8.56x9.18x
Price / BookPrice ÷ Book value/share0.32x4.67x3.89x4.84x
Price / FCFMarket cap ÷ FCF9.90x14.78x19.33x19.64x
ZCMD leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

DOCS leads this category, winning 5 of 8 comparable metrics.

DOCS delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-30 for ZCMD. ZCMD carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs ZCMD's 3/9, reflecting strong financial health.

MetricZCMD logoZCMDZhongchao Inc.IQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.
ROE (TTM)Return on equity-30.5%+22.1%+13.4%+24.4%
ROA (TTM)Return on assets-27.7%+4.7%+11.1%+20.7%
ROICReturn on invested capital-30.1%+8.7%+12.9%+20.0%
ROCEReturn on capital employed-26.3%+11.0%+13.8%+22.3%
Piotroski ScoreFundamental quality 0–93469
Debt / EquityFinancial leverage0.00x2.44x0.01x0.01x
Net DebtTotal debt minus cash-$8M$14.2B-$1.3B-$197M
Cash & Equiv.Liquid assets$8M$2.0B$1.4B$210M
Total DebtShort + long-term debt$26,083$16.2B$96M$12M
Interest CoverageEBIT ÷ Interest expense3.10x
DOCS leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — IQV and VEEV each lead in 3 of 6 comparable metrics.

A $10,000 investment in IQV five years ago would be worth $7,621 today (with dividends reinvested), compared to $146 for ZCMD. Over the past 12 months, IQV leads with a +16.5% total return vs ZCMD's -77.5%. The 3-year compound annual growth rate (CAGR) favors VEEV at -1.8% vs ZCMD's -70.9% — a key indicator of consistent wealth creation.

MetricZCMD logoZCMDZhongchao Inc.IQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.
YTD ReturnYear-to-date-44.8%-20.7%-23.4%-39.9%
1-Year ReturnPast 12 months-77.5%+16.5%-29.4%-55.4%
3-Year ReturnCumulative with dividends-97.5%-5.9%-5.2%-24.2%
5-Year ReturnCumulative with dividends-98.5%-23.8%-35.3%-50.9%
10-Year ReturnCumulative with dividends-99.3%+166.5%+519.4%-50.9%
CAGR (3Y)Annualised 3-year return-70.9%-2.0%-1.8%-8.8%
Evenly matched — IQV and VEEV each lead in 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — IQV and VEEV each lead in 1 of 2 comparable metrics.

VEEV is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than IQV's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IQV currently trades 72.3% from its 52-week high vs ZCMD's 17.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricZCMD logoZCMDZhongchao Inc.IQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.
Beta (5Y)Sensitivity to S&P 5001.21x1.33x0.77x1.03x
52-Week HighHighest price in past year$12.18$247.05$310.50$76.51
52-Week LowLowest price in past year$0.43$134.65$148.05$20.55
% of 52W HighCurrent price vs 52-week peak+17.5%+72.3%+54.2%+34.0%
RSI (14)Momentum oscillator 0–10060.458.549.660.1
Avg Volume (50D)Average daily shares traded15K1.6M2.3M2.7M
Evenly matched — IQV and VEEV each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: IQV as "Buy", VEEV as "Buy", DOCS as "Buy". Consensus price targets imply 66.5% upside for VEEV (target: $280) vs 26.3% for IQV (target: $226).

MetricZCMD logoZCMDZhongchao Inc.IQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$225.63$280.10$42.79
# AnalystsCovering analysts444222
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises2
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+4.1%+0.6%+2.3%
Insufficient data to determine a leader in this category.
Key Takeaway

DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ZCMD leads in 1 (Valuation Metrics). 2 tied.

Best OverallDoximity, Inc. (DOCS)Leads 2 of 6 categories
Loading custom metrics...

ZCMD vs IQV vs VEEV vs DOCS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ZCMD or IQV or VEEV or DOCS a better buy right now?

For growth investors, Doximity, Inc.

(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus -28. 3% for Zhongchao Inc. (ZCMD). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ZCMD or IQV or VEEV or DOCS?

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 8x versus Veeva Systems Inc. at 30. 9x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 21x versus Veeva Systems Inc. 's 1. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — ZCMD or IQV or VEEV or DOCS?

Over the past 5 years, IQVIA Holdings Inc.

(IQV) delivered a total return of -23. 8%, compared to -98. 5% for Zhongchao Inc. (ZCMD). Over 10 years, the gap is even starker: VEEV returned +519. 4% versus ZCMD's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ZCMD or IQV or VEEV or DOCS?

By beta (market sensitivity over 5 years), Veeva Systems Inc.

(VEEV) is the lower-risk stock at 0. 77β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 72% more volatile than VEEV relative to the S&P 500. On balance sheet safety, Zhongchao Inc. (ZCMD) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ZCMD or IQV or VEEV or DOCS?

By revenue growth (latest reported year), Doximity, Inc.

(DOCS) is pulling ahead at 20. 0% versus -28. 3% for Zhongchao Inc. (ZCMD). On earnings-per-share growth, the picture is similar: Doximity, Inc. grew EPS 54. 2% year-over-year, compared to -92. 7% for Zhongchao Inc.. Over a 3-year CAGR, DOCS leads at 18. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ZCMD or IQV or VEEV or DOCS?

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus -55. 5% for Zhongchao Inc. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -54. 4% for ZCMD. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ZCMD or IQV or VEEV or DOCS more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 21x versus Veeva Systems Inc. 's 1. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 1x forward P/E versus 19. 0x for Veeva Systems Inc. — 4. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 66. 5% to $280. 10.

08

Which pays a better dividend — ZCMD or IQV or VEEV or DOCS?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is ZCMD or IQV or VEEV or DOCS better for a retirement portfolio?

For long-horizon retirement investors, Veeva Systems Inc.

(VEEV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77), +519. 4% 10Y return). Both have compounded well over 10 years (VEEV: +519. 4%, ZCMD: -99. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ZCMD and IQV and VEEV and DOCS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZCMD is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock; VEEV is a mid-cap high-growth stock; DOCS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ZCMD

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 30%
Run This Screen
Stocks Like

IQV

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

VEEV

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 17%
Run This Screen
Stocks Like

DOCS

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 22%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ZCMD and IQV and VEEV and DOCS on the metrics below

Revenue Growth>
%
(ZCMD: -23.2% · IQV: 8.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.